Neurocrine randomizes first patient in Phase II schizophrenia therapy trial

Neurocrine Biosciences has randomized the first subject in its Phase II clinical trial of an investigational compound, NBI-1117568, in adult schizophrenia patients.

The multi-arm, placebo-controlled, multi-stage inpatient trial is designed to assess the safety, tolerability, efficacy, and pharmacokinetics of NBI-1117568.